KURA earnings analysis
What we found in KURA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Kura delivered $20.874 million of revenue and a $0.77 diluted EPS loss in the quarter, with revenue up approximately 16% sequentially and 39% year over year while the EPS loss improved sequentially. KOMZIFTI product revenue reached $9.1 million, up 57% quarter over quarter, supporting commercial momentum. However, Kura remains loss-making, has limited commercialization history, faces meaningful safety and reimbursement risks, and provided no explicit revenue or EPS guidance. Management’s liquidity outlook indicates $519.0 million of cash, cash equivalents and short-term investments plus $180.0 million of anticipated collaboration payments to fund the ziftomenib AML program through anticipated 2028 KOMET-017 topline results.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue accelerated sequentially and year over year
- Revenue was $20.874 million, up from $18 million in 2026 Q1 and $15 million in 2025 Q2, representing approximately 16% sequential growth and 39% year-over-year growth.
- EPS loss improved sequentially
- Diluted EPS was a loss of $0.77, improving from a loss of $0.83 in 2026 Q1 but worsening from a loss of $0.75 in 2025 Q2.
- KOMZIFTI commercial momentum
- KOMZIFTI generated $9.1 million of net product revenue, an increase of 57% quarter over quarter, and achieved a majority share of new patient starts in its class.
- Substantial liquidity supports development
- Liquidity included $519.0 million of cash, cash equivalents and short-term investments, with an additional $180.0 million in anticipated collaboration payments tied to the ziftomenib program.
- Funding runway extends to 2028
- Management stated that available liquidity is expected to fund the ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028.
- Controls remained effective
- Disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, and management reported no material changes in internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Unproven commercial execution
- The amended risk factor is particularly relevant as Kura only commenced KOMZIFTI commercialization in November 2025 and has no prior organizational experience commercializing an approved drug. KOMZIFTI is the company’s only approved product and is approved solely for adult patients with relapsed or refractory NPM1-mutated AML.
- Coverage and pricing pressure
- The amended reimbursement risk could constrain revenue because KOMZIFTI was approved in November 2025 and coverage and reimbursement for newly approved products remain uncertain. The filing notes that Medicare price negotiations can apply to single-source drugs that have been on the market for at least 7 years, while government and private-payor policies may affect pricing before then.
- Material ziftomenib safety exposure
- KOMZIFTI and ziftomenib carry material safety and post-approval risks. Treatment-related serious adverse event data include differentiation syndrome occurring in more than 10% of patients receiving ziftomenib monotherapy, and the FDA adjudicated 2 fatal cases in which differentiation syndrome could not be ruled out as a contributing factor.
- Funding dependence and dilution
- The company remains dependent on external financing despite reported liquidity. Its term-loan facility allows up to $125.0 million of term loans, but only $10.0 million was borrowed and no further draws are available; it also maintains an ATM facility permitting up to $150.0 million of equity sales, creating potential dilution if used.
- Tariffs threaten supply and costs
- The amended trade-policy risk is material because Kura relies on third-party manufacturers and suppliers, including suppliers located in China, while the filing states that tariffs could increase research and development expenses and disrupt the supply chain. The company does not own manufacturing facilities and has no current plans to build clinical or commercial-scale manufacturing capabilities.
- Expanding data-security exposure
- The amended data-privacy and security risk includes potential regulatory fines and litigation involving sensitive patient and clinical-trial data. The filing cites potential GDPR penalties of up to €20 million or 4% of annual global revenue, whichever is greater, and notes a cybersecurity incident at a former clinical-trial service provider in July 2024.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.77
- Segment
- KOMZIFTI net product revenue: $9.1 million, up 57% sequentially; no other segment revenue was disclosed.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that $519.0 million of cash, cash equivalents and short-term investments, plus $180.0 million in anticipated collaboration payments, is expected to fund the ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- Kura Oncology reported Q1 2026 results reflecting significant challenges, with revenues of $18.3 million falling short of estimates of $23.7 million, and an EPS loss of $0.83, slightly worse than the consensus loss of…
- 10-K · March 5, 2026
- Kura Oncology, Inc. has experienced a challenging year ending December 31, 2025, with a significant net loss of approximately $278.7 million amid the commercial launch of its product KOMZIFTI, alongside substantial…
- 10-Q · November 4, 2025
- Kura Oncology's Q3 2025 10-Q reveals significant challenges with revenue and EPS falling short of expectations. Total revenue came in at $21 million, substantially lower than the anticipated $62 million, and EPS…
- 10-Q · August 7, 2025
- Kura Oncology's latest 10-Q reflects a continued struggle as reported Q2 revenue of $15 million falls significantly below the estimated $95.7 million, marking a steep decline from previous quarters. EPS also…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KURA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever